In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF(165) neutralization

The stability, binding, and tissue penetration of variable new-antigen receptor (VNAR) single-domain antibodies have been tested as part of an investigation into their ability to serve as novel therapeutics. V13 is a VNAR that recognizes vascular endothelial growth factor 165 (VEGF(165)). In the pre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Millán-Gómez, Dalia, Dueñas, Salvador, Muñoz, Patricia L. A., Camacho-Villegas, Tanya, Elosua, Carolina, Cabanillas-Bernal, Olivia, Escalante, Teresa, Perona, Almudena, Abia, David, Drescher, Florian, Fournier, Pierrick G. J., Ramos, Marco A., Mares, Rosa E., Paniagua-Solis, Jorge, Mata-Gonzalez, Teresa, Gonzalez-Canudas, Jorge, Hoffman, Robert M., Licea-Navarro, Alexei, Sánchez-Campos, Noemí
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021326/
https://ncbi.nlm.nih.gov/pubmed/29963259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados